New research reveals that individuals who discontinue new slimming jabs like Mounjaro or Wegovy can put back on shed pounds much more quickly than those who stop conventional lifestyle plans.
Published data in a leading medical journal points out that while overweight people can lose a large proportion of their body weight while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"People buying such drugs should be cognizant of the danger of fast weight regain when the treatment is stopped," cautioned expert Dr. Susan Jebb.
This pace of regain implies a reversion to original mass in about a year and a half.
Weighing Treatments
The research, which examined dozens of studies involving thousands of participants, compared the results of GLP-1 agonists with other pills.
The team emphasize that people who lose weight through lifestyle changes alone usually see a less rapid weight regain—perhaps 0.1 kg a month—once they finish.
Explaining the Quick Rebound
Doctors suggest the mechanism of the jabs explains the amplified weight return.
GLP-1 drugs mimic a natural hormone called GLP-1, which controls appetite.
"Long-term administration of the hormone levels far above than normal might result in the body to produce less of its own natural hormone, and could reduce sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this hormone supplement results in hunger is no longer kept in check, making overeating a significant risk."
A Chronic Issue?
The NHS recommend the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Professionals say that, due to the likelihood of weight regain, the therapy should be considered long-term.
This view is reinforced by drug manufacturers, who say that the results "emphasize the persistent nature of obesity," similar to managing conditions like diabetes.
Patient Testimonies
Individuals who have stopped the medication explain a sudden return of appetite.
"I experienced a switch activating and I was suddenly ravenous," said a patient.
The struggle is compounded if users have not adopted sustainable lifestyle or habit modifications during treatment.
Significant Use
Survey data indicate that millions of adults in the UK have used these injections in the past year, with demand remaining high.
- Adoption is more common among females than men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the medications through private prescriptions rather than the NHS.
Finally, researchers stress that while the jabs are potent tools for shedding pounds, they are not a standalone cure and maintained weight loss hinges on ongoing lifestyle management.
